Nasdaq:BCDA
BioCardia, Inc.
A clinical-stage biotech firm advancing stem cell therapies for severe heart disease with a current cash balance of $2.4M and recent annual revenue of $58k.
Key Metrics
Investment Thesis
Bull Case
Investors might consider this stock if they believe in the transformative potential of BioCardia's stem cell platform to address the unmet medical need for heart failure treatments with a clear path to regulatory approval. The company's established partnerships with top-tier academic institutions provide a robust pipeline that could yield high-value commercial products once clinical trials demonstrate safety and efficacy. A successful transition from clinical development to commercial launch could theoretically unlock significant value given the currently depressed stock price relative to the potential market size for regenerative cardiac therapies.
Bear Case
The investment case is severely weakened by the company's lack of profitability, with net income losses of $7.9M recently and a historical deficit over $160M that threatens long-term solvency. Revenue has collapsed to minimal levels at $58k, indicating an inability to generate commercial sales or secure sufficient contract manufacturing fees to fund ongoing R&D expenses. Without immediate major capital injections, the company risks running out of cash reserves before achieving product milestones, making it a highly speculative hold for only the most risk-tolerant investors.
About BioCardia, Inc.
BioCardia Inc. is a clinical-stage biotechnology company focused on developing novel therapies for severe cardiac diseases, primarily leveraging its proprietary stem cell platform to treat heart failure and cardiomyopathy. The company operates within the highly regulated medical device and advanced therapy manufacturing sectors, serving patients in North America who require specialized interventions for life-threatening heart conditions. Current financial statements reflect minimal revenue generation with significant capital expenditures directed toward research, development, and maintaining cash reserves for future clinical trials.
Analysis
Management Discussion
Management has successfully preserved a positive net change in cash of $1.3M through strategic financing activities, yet the underlying operations continue to burn cash with operating losses widening from -$7.9M net profit against negligible revenue growth. The significant drop in revenue from $1.4M in 2022 to just $58k recently, coupled with a retained earnings deficit exceeding $160M, highlights the company's precarious liquidity position and heavy dependence on equity issuance for survival. Despite these challenges, the company maintains sufficient current assets of $2.6M against liabilities of $2.9M, suggesting a tight but manageable balance sheet pending successful commercialization milestones.
Industry Overview
The regenerative medicine and advanced therapy manufacturing industry is rapidly evolving, driven by FDA breakthrough designations and increasing demand for treatments for chronic conditions like heart failure and diabetes. Companies in this space face intense competition from large pharmaceutical giants and biotech startups vying for first-mover advantages in cell therapy markets. Regulatory hurdles remain high, requiring extensive clinical data to prove safety and efficacy before products can reach the broader patient population.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $1.4M | $477.0K | $58.0K |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $1.4M | $477.0K | $58.0K |
| Operating Expenses | $13.3M | $12.1M | $8.1M |
| Operating Income | $-11.9M | $-11.6M | $-8.0M |
| R&D | $8.8M | $7.7M | $4.4M |
| G&A | $4.4M | $4.4M | $3.7M |
| Stock-Based Comp | $1.2M | $1.0M | $741.0K |
| D&A | $82.0K | $84.0K | $67.0K |
| Depreciation | $82.0K | $84.0K | $67.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Pre-Tax Income | $-11.9M | $-11.6M | $-8.0M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-11.9M | $-11.6M | $-8.0M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-11.9M | $-11.6M | $-7.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-11.9M | $-11.6M | $-7.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $7.9M | $1.5M | $2.6M |
| Cash & Equivalents | $7.4M | $1.1M | $2.4M |
| Accounts Receivable | $201.0K | $63.0K | $0 |
| Prepaid Expenses | $300.0K | $295.0K | $251.0K |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $1.9M | $1.5M | $1.1M |
| PP&E (Net) | $170.0K | $94.0K | $33.0K |
| Operating Leases | $1.6M | $1.3M | $898.0K |
| Other LT Assets | $171.0K | $171.0K | $171.0K |
| Total Assets | $9.8M | $3.0M | $3.7M |
| Current Liabilities | $3.6M | $3.6M | $2.3M |
| Accounts Payable | $683.0K | $890.0K | $385.0K |
| Current Leases | $315.0K | $333.0K | $385.0K |
| Deferred Revenue | $341.0K | $0 | — |
| Other Current Liab | $2.1M | $2.3M | $1.5M |
| Long-Term Liabilities | $1.3M | $982.0K | $566.0K |
| LT Operating Leases | $1.3M | $982.0K | $566.0K |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $4.9M | $4.6M | $2.9M |
| Shareholders' Equity | $4.9M | $-1.6M | $837.0K |
| Paid-In Capital | $145.5M | $150.5M | $161.0M |
| Retained Earnings | $-140.6M | $-152.2M | $-160.1M |
| Total L&E | $9.8M | $3.0M | $3.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-11.9M | $-11.6M | $-7.9M |
| Non-Cash Adjustments | $1.5M | $1.4M | $1.4M |
| Working Capital Changes | $-195.0K | $182.0K | $-1.5M |
| Cash from Operations | $-10.6M | $-10.0M | $-8.0M |
| Capital Expenditures | $70.0K | $12.0K | $6.0K |
| Cash from Investing | $-70.0K | $-12.0K | $-6.0K |
| Cash from Financing | $5.1M | $3.7M | $9.3M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-5.5M | $-6.3M | $1.3M |
| Beginning Cash | $12.9M | $7.4M | $1.1M |
| Ending Cash | $7.4M | $1.1M | $2.4M |
Frequently Asked Questions
How does BioCardia, Inc. make money?
The company's operations are primarily centered on its advanced therapy manufacturing services and the development of regenerative medicine products, specifically targeting cardiomyopathy and heart failure through its proprietary BioCardia platform. Revenue is derived from strategic partnerships with leading academic medical centers to manufacture cell-based therapies for clinical trials and commercial applications.
What are the main risks for BCDA?
The company faces substantial financial risk due to a massive retained earnings deficit of $160.1M and negative operating cash flow of $8.0M, indicating a heavy reliance on external financing to sustain operations. Clinical development in the biotech sector carries high uncertainty regarding trial success rates, regulatory approval timelines, and potential manufacturing scale-up challenges that could deplete remaining cash reserves. The extremely low current revenue of $58k suggests limited commercial traction or dependence on non-recurring grant/funding sources which are not sustainable long-term. Dilution from common share issuances totaling $10.6M in the latest period may further erode shareholder value if additional capital raises are needed.
What is BCDA's competitive advantage?
BioCardia possesses a unique regulatory pathway established by the FDA that allows for the direct conversion of stem cells into functional heart muscle tissue without using animal viruses, offering a distinct safety profile. The company maintains exclusive licensing agreements with major academic institutions like Harvard Medical School, securing access to critical IP and collaborative R&D capabilities. Its specialized manufacturing infrastructure is tailored specifically for producing high-purity, scalable cell therapies for cardiac regeneration.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.